Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CNEY vs BON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BON Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–1 Matrix Metrics)

BON Overall Winner 6-Pillar Tally: CNEY 1 – 4 BON (1 Tie) Matrix Metrics: CNEY 1 – 8 BON

As of Nov 17, 2026, Bon Natural Life Limited Class A (BON) is the stronger overall head-to-head candidate over CN Energy Group Inc. Class A (CNEY) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CNEY carries a Unified Composite Score of 35.1/100 (SELL) at $0.44 (N/M Forward P/E, -138.5% operating margin), whereas BON carries 52.3/100 (HOLD) at $1.02 (2.4x Forward P/E, -45.5% operating margin).

  • Technical & Structure Timing Caution: CNEY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile BON is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNEY vs BON
CNEY NASDAQ
CN Energy Group Inc. Class A Ordinary Shares
Industrial Organic Chemicals
$0.44
-8.73% 1D
Market Cap $2.6M
TTM Revenue $37M
Forward P/E N/M
Beta / 30D Vol 0.70β · 109% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 15.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $0.48 · SMA50: $0.50
BON NASDAQ Head-to-Head Winner
Bon Natural Life Limited Class A Ordinary Shares
Medicinal Chemicals & Botanical Products
$1.02
-5.96% 1D
Market Cap $9.0M
TTM Revenue $19M
Forward P/E 2.4x
Beta / 30D Vol -0.06β · 35% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 50.0 Mom 73.6
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 25
RSI-14: 25.4 · SMA20: $1.12 · SMA50: $1.14

6-Pillar Scorecard Institutional Category Breakdown (CNEY 1 – 4 BON)

Columns: Metric · CNEY · BON
1. Valuation Multiples BON
Forward P/E N/M 2.4x
Trailing P/E N/M 2.4x
PEG Ratio N/M N/M
EV / Revenue 0.1x 0.5x
2. Growth & Scale CNEY
Revenue Growth (YoY) +8.2% +1.9%
Earnings Growth (YoY) +76.7% -41.0%
TTM Revenue (USD) $37M $19M
Market Cap $2.6M $9.0M
3. Profitability & Quality BON
Gross Margin 1.1% 22.1%
Operating Margin -138.5% -45.5%
Net Profit Margin -183.1% -60.4%
Return on Equity (ROE) -84.3% -21.8%
4. Balance Sheet & Cash Flow BON
Cash Generation (TTM) -$50M EBITDA -$7.3M EBITDA
Cash Flow Margin -136.7% EBITDA Mgn -38.8% EBITDA Mgn
Net Cash / Leverage $4.74 Book/Sh · -84.3% ROE $8.18 Book/Sh · -21.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BON
OpEx & R&D Intensity N/A 67.6% of Rev ($13M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Specialty Chemicals Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNEY (1) vs BON (8)
Institutional Metric CNEY BON Criterion Row Edge
Market Capitalization
Scale
$2.6M $9.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 2.4x Lower Multiple BON
Forward P/E Ratio
Valuation
N/M 2.4x Lower Multiple BON
Revenue Growth (YoY)
Growth
+8.2% +1.9% Higher Growth CNEY
Operating Margin (TTM)
Profitability
-138.5% -45.5% Higher Margin BON
Net Profit Margin
Profitability
-183.1% -60.4% Higher Margin BON
Return on Equity (ROE)
Capital Efficiency
-84.3% -21.8% Higher ROE BON
52-Week Range Position
Momentum
5% ($0–$3) 8% ($1–$2) Stronger Trend BON
Beta / 30D Volatility
Risk Regime
0.70β · 109% Vol -0.06β · 35% Vol Lower Realized Risk BON
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 52.3 / 100 (HOLD) Higher Composite BON
Trailing 12M Revenue (USD)
Operating Scale
$37M $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
1.1% 22.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M EBITDA ($4.74 Book/Sh · -84.3% ROE) -$7.3M EBITDA ($8.18 Book/Sh · -21.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNEY +18.96 pp
CNEY: +10.58% · BON: -8.38%
3M Horizon BON +17.39 pp
CNEY: -27.48% · BON: -10.09%
6M Horizon BON +52.26 pp
CNEY: -72.8% · BON: -20.54%
1Y Horizon BON +27.03 pp
CNEY: -72.8% · BON: -45.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNEY vs BON. Trailing 12-month operating profitability (CNEY -138.5% vs BON -45.5%) and valuation multiples (CNEY N/M vs BON 2.4x Forward P/E) are benchmarked directly in Pillar 4 below.

CNEY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37M
Gross Margin1.1%
Op. Margin-138.5%
ROE / Fwd P/E-84.3% · N/M
BON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin22.1%
Op. Margin-45.5%
ROE / Fwd P/E-21.8% · 2.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNEY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CNEY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BON UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNEY Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $2.6M market capitalization and -138.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BON Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $9.0M market capitalization and -45.5% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($13M)
90D Engineering Disclosures 0 Published

Investor FAQ CNEY vs BON Key Questions & Quantitative Answers

As of Nov 17, 2026, Bon Natural Life Limited Class A (BON) is the stronger overall head-to-head candidate over CN Energy Group Inc. Class A (CNEY) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CNEY carries a Unified Composite Score of 35.1/100 (SELL) at $0.44 (N/M Forward P/E, -138.5% operating margin), whereas BON carries 52.3/100 (HOLD) at $1.02 (2.4x Forward P/E, -45.5% operating margin). Technical & Structure Timing Caution: CNEY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile BON is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNEY leads the Growth & Scale pillar: CNEY posts +8.2% YoY revenue growth and +76.7% YoY earnings growth on $37M TTM revenue (1.1% gross margin, -138.5% operating margin), compared with BON at +1.9% YoY revenue growth and -41.0% YoY earnings growth on $19M TTM revenue (22.1% gross margin, -45.5% operating margin). On trailing 12-month operating scale, CNEY generates $37M in USD-normalized revenue versus $19M for BON. In operating R&D and SG&A reinvestment, CNEY deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($13M) (0 disclosures) for BON.

BON screens cheaper on headline valuation multiples. CNEY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-136.7% EBITDA margin), whereas BON trades at 2.4x Forward P/E, 2.4x Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-38.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNEY (-84.3% ROE) versus BON (-21.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CNEY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.70β · 109% Vol realized risk). By comparison, BON carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.06β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.